Pricing and Market Access Considerations for Cell and Gene
Pricing and Market Access Considerations for Cell and Gene In the past two years, four cell and gene therapies have entered the U.S. market at unprecedented prices. Most recently, Zolgensma launched at a price of $2.1 million for a one-time treatment. Payers view these new therapies as having moderate to high clinical value but have significant concerns around long term durability of effect. For example, will [...]